Medtronic's most recent trend suggests a bullish bias. One trading opportunity on Medtronic is a Bull Put Spread using a strike $91.00 short put and a strike $86.00 long put offers a potential 25% return on risk over the next 9 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $91.00 by expiration. The full premium credit of $1.00 would be kept by the premium seller. The risk of $4.00 would be incurred if the stock dropped below the $86.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Medtronic is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Medtronic is bullish.
The RSI indicator is at 30.21 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Medtronic
Diabetics are hacking old insulin pumps to make them smarter — here's what happened when I tried it
Sat, 03 Nov 2018 13:00:00 +0000
Type 1 diabetes is a disease that affects more than 1.2 million Americans. It's a disease that impairs the body's ability to produce the hormone insulin, which normally comes from the pancreas. Managing blood sugars can be very difficult, and patients use a pump to help mimic the activity of the pancreas.
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
Thu, 01 Nov 2018 21:50:09 +0000
Medtronic (MDT) closed at $91.55 in the latest trading session, marking a +1.93% move from the prior day.
IBD Stock Of The Day Breaks Out On Strong Quarterly Report, Outlook
Thu, 01 Nov 2018 20:19:23 +0000
Repligen is the IBD Stock Of The Day after the bioprocessor broke out for the second time this year on its 15th straight quarter of double-digit sales growth. Shares rose.
United Therapeutics (UTHR) Q3 Earnings Beat but Stock Dips
Thu, 01 Nov 2018 15:14:03 +0000
United Therapeutics (UTHR) beats estimates for both earnings and sales in the third quarter but shares sink 10%.
IntriCon (IIN) to Report Q3 Earnings: What's in the Cards?
Wed, 31 Oct 2018 15:20:03 +0000
IntriCon's (IIN) robust medical and hearing health businesses are likely to drive its third-quarter 2018 results.
Also on Market Tamer…
Follow Us on Facebook